Key facts
- Tandem Diabetes received the CE mark for expanded uses of its insulin pump.
- The approval allows the pump to be used with additional continuous glucose monitors.
- The approval allows the pump to be used with additional automated insulin delivery features.
Tandem Diabetes has announced that it has received the CE mark for expanded uses of its insulin pump. This regulatory approval signifies that the device meets the essential requirements for safety and performance within the European Economic Area. The expanded uses permit the insulin pump to be integrated with a wider range of continuous glucose monitoring (CGM) systems and to utilize additional automated insulin delivery (AID) features. This development is expected to enhance the flexibility and functionality of the pump for individuals managing diabetes.